The deficiency of galectin-3 in stromal cells leads to enhanced tumor growth and bone marrow metastasis

Página do item simplificado
dc.contributor.authorPEREIRA, JONATHAS X.
dc.contributor.authorAZEREDO, MARIA C.B.
dc.contributor.authorMARTINS, FELIPE S.
dc.contributor.authorCHAMMAS, ROGER
dc.contributor.authorOLIVEIRA, FELIPE L.
dc.contributor.authorSANTOS, SOFIA N.
dc.contributor.authorBERNARDES, EMERSON S.
dc.contributor.authorEL-CHEIKH, MARCIA C.
dc.coverageInternacionalpt_BR
dc.date.accessioned2016-11-11T09:57:17Z
dc.date.available2016-11-11T09:57:17Z
dc.date.issued2016pt_BR
dc.description.abstractBackground: Galectin-3 is a multifunctional β-galactoside-binding lectin that once synthesized, is expressed in the nucleus, cytoplasm, cell surface and in the extracellular environment. Because of its unique structure, galectin-3 can oligomerize forming lattice upon binding to multivalent oligossacharides and influence several pathologic events such as tumorigenesis, invasion and metastasis. Methods: In our study, balb/c Lgals3+/+ and Lgals3−/− female mice were inoculated in the fourth mammary fat pad with 4T1 breast cancer cell line. The primary tumor, inguinal lymph nodes and iliac bone marrow were evaluated 15, 21 and 28 days post-injection. The primary tumor growth was evaluated by measuring the external diameter, internal growth by ultrasound and weight of the excised tumor. The presence of cancer cells in the draining lymph nodes and iliac crest bone marrow were performed by immunohistochemistry, PCR and clonogenic metastatic assay. Results: In this study we demonstrated that the deletion of galectin-3 in the host affected drastically the in vivo growth rate of 4T1 tumors. The primary tumors in Lgals3−/− mice displayed a higher proliferative rate (p < 0,05), an increased necrotic area (p < 0,01) and new blood vessels with a wider lumen in comparison with tumors from Lgals3+/+ mice (P < 0,05). Moreover, we detected a higher number of 4T1-derived metastatic colonies in the lymph nodes and the bone marrow of Lgals3−/− mice (p < 0,05). Additionally, healthy Lgals3−/− control mice presented an altered spatial distribution of CXCL12 in the bone marrow, which may explain at least in part the initial colonization of this organ in Lgals3−/− injected with 4T1 cells. Conclusions: Taken together, our results demonstrate for the first time that the absence of galectin-3 in the host microenvironment favors the growth of the primary tumors, the metastatic spread to the inguinal lymph nodes and bone marrow colonization by metastatic 4T1 tumor cells.pt_BR
dc.identifier.citationPEREIRA, JONATHAS X.; AZEREDO, MARIA C.B.; MARTINS, FELIPE S.; CHAMMAS, ROGER; OLIVEIRA, FELIPE L.; SANTOS, SOFIA N.; BERNARDES, EMERSON S.; EL-CHEIKH, MARCIA C. The deficiency of galectin-3 in stromal cells leads to enhanced tumor growth and bone marrow metastasis. <b>BMC Cancer</b>, v. 16, n. 1, 2016. DOI: <a href="https://dx.doi.org/10.1186/s12885-016-2679-1">10.1186/s12885-016-2679-1</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/26800.
dc.identifier.doi10.1186/s12885-016-2679-1pt_BR
dc.identifier.fasciculo1pt_BR
dc.identifier.issn1471-2407pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0029-7313
dc.identifier.percentilfi57.37
dc.identifier.urihttp://repositorio.ipen.br/handle/123456789/26800
dc.identifier.vol16pt_BR
dc.relation.ispartofBMC Cancerpt_BR
dc.rightsopenAccesspt_BR
dc.subjectproteins
dc.subjectlectins
dc.subjectgalactose
dc.subjectmammary glands
dc.subjectneoplasms
dc.subjecttumor cells
dc.subjectgrowth
dc.subjectconnective tissue cells
dc.subjectbone marrow
dc.subjectmetastases
dc.titleThe deficiency of galectin-3 in stromal cells leads to enhanced tumor growth and bone marrow metastasispt_BR
dc.typeArtigo de periódicopt_BR
dspace.entity.typePublication
ipen.autorEMERSON SOARES BERNARDES
ipen.autorSOFIA NASCIMENTO DOS SANTOS
ipen.codigoautor12099
ipen.codigoautor14464
ipen.contributor.ipenauthorEMERSON SOARES BERNARDES
ipen.contributor.ipenauthorSOFIA NASCIMENTO DOS SANTOS
ipen.date.recebimento16-11pt_BR
ipen.identifier.fi3.288pt_BR
ipen.identifier.ipendoc22660pt_BR
ipen.identifier.iwosWoSpt_BR
ipen.identifier.ods3
ipen.range.fi3.000 - 4.499
ipen.range.percentilfi50.00 - 74.99
ipen.type.genreArtigo
relation.isAuthorOfPublication8115c8bd-822c-4f5a-9f49-3c12570ed40a
relation.isAuthorOfPublicationab78881a-78eb-42be-a463-aaf80e70de3d
relation.isAuthorOfPublication.latestForDiscoveryab78881a-78eb-42be-a463-aaf80e70de3d
sigepi.autor.atividadeSANTOS, SOFIA N.:14464:-1:Npt_BR
sigepi.autor.atividadeBERNARDES, EMERSON S.:12099:-1:Npt_BR
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
22660.pdf
Tamanho:
1.83 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar
Coleções
Periódicos